HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PMN
ProMIS Neurosciences, Inc.
There isn't enough reported data to score PMN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PMN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PMN's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PMN PE Valuation
PMN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PMN Forward outlook
There aren't enough analyst estimates for PMN to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over PMN on earnings, with more consistent year-over-year improvement.
PMN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$8.89 | +$9.81 |
| Q2 2026 | -$14.00 | -$9.05 |
| Q1 2026 | -$19.97 | -$19.02 |
| Q4 2025 | -$23.96 | -$23.51 |
| Q3 2023 | -$51.24 | -$7.24 |
| Q2 2023 | -$67.74 | -$40.43 |
| Q1 2023 | -$70.49 | -$51.86 |
| Q4 2022 | -$62.39 | -$22.63 |
PMN is still losing money, but far less than before: $8.89 per share over the past year, against $70.49 at its worst in early 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PMN Quarterly Revenue
PMN's revenue is growing: $3,612 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2022 | -95778% | N/A |
| Q4 2021 | -123523% | N/A |
| Q3 2021 | -40368% | N/A |
| Q2 2020 | 105445% | N/A |
| Q4 2019 | -193205% | N/A |
PMN's operating margin was −95778% last quarter, up 97427 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PMN on cash generation, producing positive trailing cash flow while its opponent burns cash.
PMN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.4M | +$678.5K |
| Q2 2026 | -$10.4M | -$6.5M |
| Q1 2026 | -$12.4M | -$7.5M |
| Q4 2025 | -$9.3M | -$566.9K |
| Q3 2025 | -$10.1M | -$3.4M |
| Q2 2025 | -$3.9M | -$2.3M |
| Q1 2025 | -$4.9M | +$5.4M |
| Q4 2022 | -$4.6M | -$485.3K |
PMN has burned cash in almost every quarter: −$41M over the past year, against −$28M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PMN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PMN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +974 shares |
| 1 year | +368% | +7.2M shares |
| 3 years | +2564% | +8.8M shares |
| 5 years | +4383% | +8.9M shares |
| Available history | +5146% | +9M shares |
PMN has 9M diluted shares, up 368% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PMN Net Leverage
PMN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PMN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 5.5 | Oversold |
PMN's weekly RSI is 30 (neutral) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PMN PE vs Healthcare Sector
PMN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PMN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.21 | 52% below |
| 20 week MA | $11.2 | 69% below |
| 50 week MA | $11.8 | 70% below |
| 100 week MA | $13.6 | 74% below |
| 200 week MA | $38.6 | 91% below |
PMN is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over PMN on returns for 2026, with the stronger performance.
PMN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $195.0 | $90.0 | -54% |
| 2021 | $90.0 | $165.0 | +83% |
| 2022 | $165.0 | $119.3 | -28% |
| 2023 | $119.3 | $28.8 | -76% |
| 2024 | $28.8 | $22.5 | -22% |
| 2025 | $22.5 | $7.66 | -66% |
| 2026 YTD | $7.66 | $3.48 | -55% |
PMN has finished four years in a row lower, and it's down 55% so far in 2026.